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NEURAL REGENERATION RESEARCH 
a PERSPECTIVE 
Recent advances on the role of long 
non-coding RNAs in Alzheimer's 
disease 
Dementia is a progressive cognitive impairment that affects the activities 
of daily living. Alzheimer's disease (AD) is the most common form of the 
dementia worldwide accounting for 60-80% of all dementia cases. With an 
estimated cost exceeding $290 billion in the USA, understanding and devel-
opment of future therapeutic strategies is vital. In this perspective, we will 
be examining the current thinking of AD research and therapeutic strate-
gies, while proposing a possible new direction for diagnosis, understanding, 
and treatment targets. Non-coding RNA accounts for the largest popu-
lation of the human transcriptome. Long noncoding RNA (lncRNA) is a 
recent molecule of interest in the biomedical research which is non protein 
coding and is of length greater than 200 nucleotides. LncRNAs have been 
shown to play diverse roles within the cells such as posttranscriptional and 
posttranslational regulation, chromatin modulation, and protein complex 
organization. Given the flexible and diverse role in disease pathophysiology, 
lncRNAs may serve as novel therapeutic targets for diagnosis and treatment. 
Evidently, recent studies showed that dysregulation of lncRNA influences 
the clinical course of tumorigenesis, neurological disorders, cardiovascular 
disease, diabetes, and acquired immunodeficiency syndrome (Kazimierczyk 
et al., 2020) . This indicates that lncRNA can provide a unique avenue of re-
search and possible therapeutic targets in AD. 
Current AD research: AD is the most common form of dementia, char-
acterized by progressive neuronal death associated with neuropathological 
findings of neurofibrillary tangles and senile plaques. Despite considerable 
advances in the knowledge of AD pathogenesis, we know little about how to 
prevent or delay the ongoing neurodegenerative process. Therefore, a deeper 
understanding of the molecular mechanisms involved in AD pathogenesis is 
essential, which would contribute to the development of a novel therapeutic 
target. The vast majority of AD occurs on a seemingly sporadic basis. While 
both genetic and environmental factors may drive sporadic AD, the £4 allele 
of apolipoprotein E gene is a major genetic risk factor for the AD develop-
ment. However, it has been found that a familial form of AD is driven by 
mutations in amyloid precursor protein (APP), presenilin I (PSENI), and 
presenilin 2 (PSEN2), which occurs much earlier than sporadic AD, between 
the ages of 30 and 50 years. Mutations in the genes APP/PSENI/PSEN2 for 
familial form of AD or dysfunction in apolipoprotein E leads to an unfavor-
able accumulation of the amyloid beta (AP) peptide. This eventually leads to 
widespread neuronal/synaptic dysfunction and ultimately dementia (Selkoe 
and Hardy, 2016). Unfortunately, attempts to ameliorate the disease course 
by removing AP or reducing its production have been largely unsuccess-
ful. The failure of drugs targeting AP deposition in the brain has fueled an 
increasing interest in alternative disease-causing mechanisms. The recent 
progress of deep-transcriptome sequencing and genome-wide analyses have 
identified several dysregulated lncRNAs in AD, but the expression patterns, 
interacting proteins, and biological functions of these lncRNAs in AD re-
main largely unexplored. Thus, understanding how lncRNAs regulate neu-
ronal function in the brain may allow for the development of effective ther-
apies for AD and related neurodegenerative diseases. Interestingly, lncRNA 
biology is the rapidly emerging area of focus in biomedical research field. It 
is evident from the exponential increase of published articles on lncRNA. 
As searched on PubMed, lncRNA and cancer showed 34 articles in 2010 and 
3174 in 2019. Evidently, lncRNA in AD has gained some attention with 85 
articles on PubMed in 2019. This shows lncRNA as a potential and novel tar-
get in AD, which needs to be explored for its mechanism and etiology. 
LncRNAs in AD: Once considered transcriptional noise, lncRNAs are as-
sociated with specialized functions in specific cell types. They are predomi-
nantly located in the nucleus helping in one of their functions of epigenetic 
regulation (Luo and Chen, 2016) . With diverse roles, cell specific functions, 
and dysregulation linked to cancer, epilepsy, cardiovascular, neurodegen-
erative, and genetic diseases, it stands to reason that lncRNA would confer 
promoting or inhibiting effects in the development of AD, similar to its 
contribution in other diseases (Luo and Chen, 2016). Although, the role of 
lncRNAs in AD are fairly studied over the past few years, the mechanisms 
of its involvement in neurodegeneration and cognitive impairment are un-
known. Recently, several lncRNAs, BACEI-AS, SIA, 17A, NDM29, BC200, 
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MALATI, BDNF-AS and NAT-Radl8 have been shown to play a role in 
AD. These lncRNAs regulate synaptic plasticity, APP processing, tau phos-
phorylation and inflammation, major causal agents in AD (Figure I; Corti-
ni et al., 2019). In addition, it has been suggested that lncRNAs also interact 
with miRNAs and regulate a broad range of biological processes through 
their crosstalk with miRNAs. Besides that, a recently identified lncRNA 
EBF3-AS plays a role in promotion of neuronal apoptosis in a murine mod-
el of AD and was abnormally expressed in the brains of AD patients ( Gu et 
al., 2018) . The conserved anti-sense noncoding RNA P-secretase-1 (BACEI-
AS) is highly expressed in the brains of AD patients and mouse models 
of AD and drives feed-forward regulation of BACEI (Faghihi et al. 2008). 
BACE!-AS increases in response to cell stressors, suggesting its role in over-
all progression of AD. A study by Zhang and coworkers demonstrated that 
silencing ofBACE!-AS by short interfering RNA reduces the production of 
AP1-42 oligomers in cellular system and improves cognitive function through 
regulation of BACEI, and tau phosphorylation in in vivo (Zhang et al., 
2018). Therefore, it is conceivable that BACEI-AS could serve as a potential 
biomarker for diagnosis and therapeutic target for the treatment of AD. 
Similarly, lncRNAs SIA, 17 A, and NDM29 have been shown to increase AP 
abundance (Luo and Chen, 2016). The lncRNA SIA has been shown in a 
recent study to drive a splicing shift in variant A of SORLI. The decrease in 
SORLI variant A leads to an impaired processing of APP leading to increase 
in the formation of Ap. Neuroblastoma differentiation marker 29 (NDM29) 
drives neuroblastoma cell differentiation to nonmalignant neuron-like phe-
notypes. In cells dependent upon NDM29 maturation, there is an increased 
synthesis of APP and subsequent AP formation and secretion ( Cortini et al., 
2019). The lncRNA BC200 regulates cell viability and apoptosis via mod-
ulating the expression of BACEI and its level is significantly upregulated 
in the AD patients (Mus et al., 2007). Increased expression of NAT-Radl8 
leads to dysregulation of DNA Repair mechanism leading to an increase in 
neuron sensitivity to apoptosis and AD progression (Luo and Chen, 2016). 
LncRNA MALATI was originally identified in lung cancer and found to 
promote cell proliferation and metastasis in various cancers such as lung, 
ovarian, and pancreatic cancer. However, in a recent study inhibition of 
MALATI has been shown to inhibit neuron apoptosis and promote neur-
ite outgrowth (Ma et al., 2019) . This evidence suggests that MALATI can 
provide a new route in the understanding of the mechanism of AD disease 
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Figure I A schematic diagram representing the possible lncRNA 
neuroprotective function in Alzheimer's disease. 
LncRNA might function as Decoy and/or Scaffold to sequester secretase 
enzyme and hence hinders enzyme function, decreasing amyloid beta (AP) 
aggregation. It can sequester kinases to decrease tau hyperphosphorylation. 
LncRNA can also decrease neurofibrillary tangles burden phosphorylated, 
by keeping hyperphosphorylated tau proteins apart. APP: Amyloid precusor 
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an important role in the regulation of BDNF protein expression. Inhibition 
of BDNF-AS increases mRNA levels of BDNF, enhances protein levels of 
BDNF and triggers neuronal differentiation. Given the role ofBDNF in AD 
and other neurological disorders, pharmacological inhibitors of BDNF-AS 
may have significant therapeutic potential in the treatment of AD. These 
findings provided proof-of-concept evidence and support for the potential 
roles of lncRNA in AD pathogenesis. Understanding the molecular mech-
anisms underlying lncRNA dysregulation in AD may provide new insights 
into AD pathophysiology and open new therapeutic avenues. 
Novel biomarkers: Early diagnosis of any disease more often leads to better 
outcomes. The unique aspects of lncRNA make it a leading candidate as a 
diagnostic and/or prognostic biomarker. LncRNA has been mostly char-
acterized in cancer and has also been shown to be a biomarker candidate 
in other diseases too. While recent studies on lncRNAs have shown them 
to be aberrantly expressed, and some appear to be cancer specific. The spe-
cific expression, stability in bodily fluids, and increased expression often 
correlating to the severity of the disease making lncRNAs an attractive can-
didate for non-invasive screening. LncRNAs are already in clinical trials as 
biomarkers. LncRNA PCA3 is one of these, due to its high levels and spec-
ificity to prostate cancer along with its detectable limits in urine (Bhan et 
al., 2017). HOTAIR circulation has been suggested as a possible diagnosis's 
marker for breast cancer. In addition, a recent study by Tan and colleagues 
have demonstrated that HOTAIR is a peripheral biomarker for glioblas-
toma multiforme patients (Tan et al., 2018). The expression of BACEl-AS 
is upregulated in blood samples from AD patients, indicating BACEl-AS 
may serve as a plausible biomarker for AD (Zhang et al., 2018). Similarly, 
increased lncRNA SIA expression has been detected in the plasma of AD 
patients, suggesting lncRNA SIA in plasma could be used as a potential 
diagnostic and prognostic biomarker for AD. MALATl expression can be 
used as marker for lung cancer. Interestingly, a study by Yoa et al. (2016) re-
ported decreased lncRNA MALATl levels in the cerebrospinal fluid of AD 
patients compared with the control group, suggesting lncRNA MALATl 
monitoring in cerebrospinal fluid could serves a diagnostic marker for AD. 
The flexibility demonstrated in cancer and other neural diseases along with 
evidence suggesting lncRNA playing a key role in the development of AD 
indicate, that lncRNA might provide effective candidates for non-invasive 
screening for AD. 
Conclusion: The last 25 years of AD research and therapeutic development 
has been focused on understanding and preventing the accumulation of 
toxic A~. The amyloid cascade hypothesis has provided a strong backbone 
that has led to great leaps in knowledge when it comes to AD. This back-
bone has also led to stagnation in AD diagnosis and therapeutics. This is 
evident in the non-existence of disease modifying therapeutic options and 
earlier detection of AD. LncRNA provides a novel route of research for the 
development of new therapies and diagnostic markers for AD. Recent stud-
ies have provided important insights of the biological function and clinical 
relevance of lncRNAs in AD. Although, there is increasing recognition that 
lncRNAs have been implicated in AD pathogenesis, but it remains unknown 
how they influence AD development and progression. Understanding the 
regulatory function and molecular mechanisms of lncRNAs in AD patho-
physiology will fuel the development of innovative diagnosis strategies and 
potential therapeutic targets. LncRNA is already beginning to be uncov-
ered as a potential key player in the development of AD as shown in the 
studies mentioned above. However, it is not just a promotive agent in AD 
as demonstrated by MALATl expression, leading to inhibition of neuron 
apoptosis and neurite growth. Moreover, findings on the role of lncRNAs 
in cancers and glioblastoma may shed new light on understanding of mo-
lecular mechanisms of lncRNA in AD. With AD the most common form 
of dementia, and more than triple the current estimated 44 million people 
to live with dementia worldwide by 2050, there is an urgent need for new 
therapies and diagnostic tools for AD. Undoubtedly, activators or inhibitor 
of lncRNAs will provide a potential and novel strategy for the treatment of 
AD. Interestingly, antisense oligonucleotides (ASOs) targeting aberrantly 
expressed lncRNAs may represent a feasible treatment for AD. Develop-
ment of specific ASOs downregulating BACEI-AS, SIA, 17A, NDM29 and 
BDNF-AS may represent novel and potential therapeutic strategy in order 
to regulate A~ production, inflanunation and tau phosphorylation in AD. 
However, the major challenge in using ASOs in neurodegenerative disor-
ders is the poor bioavailability, susceptible nuclease degradation nature, and 
limited blood-brain barrier permeability. EVs, small nanovesicles, also fre-
quently referred to as exosomes, recently been recognized as potential drug 
delivery systems for therapeutic interventions. It is desirable to load ASOs 
targeting lncRNAs in EVs and examine their therapeutic effects on AD-re-
lated neuropathology and cognitive function. Furthermore, lncRNAs may 
be used as potential biomarker for clinical assessment of AD stages, as their 
abnormal expression pattern can be easily detected in plasma or cerebrospi-
nal fluid of AD patients. The use of lncRNAs as diagnostic and prognostic 
markers has already been exploited in the cancer research but more research 
is needed to establish lncRNAs as biomarker for AD patients. In conclu-
sion, the role of lncRNAs in the AD pathogenesis is largely unexplored and 
understanding the molecular mechanisms of lncRNAs in AD will uncover 
more avenues to early diagnosis and effective therapies. 
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